# Alpine Immune Sciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/alpine-immune-sciences

- Industry: Biotechnology
- Headquarters: Seattle, US
- Website: www.alpineimmunesciences.com/
- Total disclosed funding: $11M
- Latest round: Series A (Jun 10, 2016)
- Investors on record: 3

## About

Founded in 2015 and based in Washington, US, Alpine Immune Sciences, Inc., formerly known as Nivalis Therapeutics, Inc., operates as a biopharmaceutical that provides development of immunotherapies for autoimmune and inflammatory diseases. The company is listed on the Nasdaq under the ticker symbol ALPN. In April 2024, Vertex Pharmaceuticals Incorporated agreed to acquire Alpine Immune Sciences, Inc. from Alpine BioVentures, Avidity Partners, BVF Partners, Deerfield Management, Decheng Capital, Frazier Healthcare Partners, Logos Capital, Omega Funds, OrbiMed Advisors, RA Capital, TCG Crossover Management, and Wellington Management for USD 4.9 billion, or USD 65 per share. The transaction is expected to be completed this second quarter of 2024.

The company's diverse pipeline includes programs like Povetacicept (ALPN-303), a dual B cell cytokine antagonist for systemic lupus erythematosus and glomerulonephritis. Alpine also has partnered programs such as Acazicolcept (ALPN-101), a dual CD28/ICOS antagonist in Phase 2 trials for systemic lupus erythematosus.

## Funding rounds

- Series A, Jun 10, 2016, $10M — Frazier Healthcare Partners, OrbiMed Advisors, Alpine BioVentures
- Seed, Jan 23, 2015, $1M — Alpine BioVentures

## Investors

- Alpine BioVentures (https://capitalatlas.ai/funds/alpine-bioventures) — Seed, Series A
- Frazier Healthcare Partners (https://capitalatlas.ai/funds/frazier-healthcare-partners) — Series A
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A